Pharmacoeconomics of linezolid

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 987-1000

  Grau, Santiago ^a   Rubio Terrés, Carlos ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Cost analysis; Gram positive bacterial infections; Linezolid; Teicoplanin; Vancomycin

Indexed keywords

DAPTOMYCIN; FLUCLOXACILLIN; IMIPENEM; LINEZOLID; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HEALTH CARE PLANNING; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; SURGICAL INFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MODELS, ECONOMETRIC; OXAZOLIDINONES; QUALITY OF LIFE; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 42949153793     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.987     Document Type: Review

References (75)

1. Akins RL, Haase KK. Gram-positive resistance: pathogens, implications, and treatment options - insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2005;25:1001-10
2. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82
3. Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. Am Fam Phys 2002;65:663-70
4. Raboud J, Saskia R, Simor A, et al. Modeling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital. Infect Control Hosp Epidemiol 2005;26:607-15
5. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005;40:562-73
6. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance System report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98
7. Tacconelli E, Venkataraman L, de Girolami PC, D'agata EM. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus health-associated strains. J Antimicrob Chemother 2004;53:474-9
8. Naimi TS, Ledell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84
9. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44
10. Tiemersma EW, Bronzwaer SL, Lytikäinen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999 - 2002. Emerg Infect Dis 2004;10:1627-34
11. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9
12. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999;5:9-17
13. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-8
14. Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus. Review and analysis of the literature. Pharmacoeconomics 2007;25:751-68
15. Shorr A. Epidemiology of Staphylococcus resistance. Clin Infect Dis 2007;45:S171-6
16. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999;353:1587-8
17. Mohr JF, Murria BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536-42
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement Standard M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007
19. Borraz C. Epidemiología de la resistencia a meticilina en cepas de Staphylococcus aureus aisladas en hospitales españoles. Tesis Doctoral. Barcelona: Universidad de Barcelona, 2006. Available from: http://www.tesisenxarxa.net/TESIS_UB/AVAILABLE/TDX-1027106-105221//CBO TESIS_DOCTORAL.pdf [Last accessed November 2007].
20. Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chem 2003;51 (Suppl S2):ii37-44
21. Abramson MA, Sexton DJ. Nosocomial methicillin resistant and methicillin susceptible Staphylococcus aureus primary bacteraemia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-11
22. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38:1377-82
23. Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc 2003;51:10-6
24. Cosgrove SE, Youlin Q, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect control Hosp Epidemiol 2005;26:166-74
25. Coast J, Smith RD. Antimicrobial resistance: cost and containment. Expert Rev Antiinfect Ther 2003;1:241-51
26. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microb Infect Dis 2005;52:113-22
27. Lodise TP, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 2007;27:1001-12
28. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-8
29. Azanza JR, Barberán J, García-Rodríguez JA, et al. Recomendaciones para el tratamiento de las infecciones nosocomiales producidas por microorganismos grampositivos. Rev Esp Quimioterap 2004;17:271-88
30. Agencia Española del Medicamento y Protuductos Sanitarios. Summary of product characteristics: Zyvoxid (linezolid). March 2007. Available from: https://sinaem4.agemed.es/consaem/especialidad.do?metodo= verFichaWordPdf&codigo=64107&formato=pdf&formulario= FICHAS [Last accessed November 2007]
31. Food and Drug Administration: Zyvox (linezolid injection, linezolid tablets, linezolid for oral suspension). Available from: http://www.fda.gov/cder/foi/label/2005/021130s008,009,021131s009,010, 021132s008,0091bl.pdf [Last accessed November 2007].
32. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12
33. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92
34. Kollef MH, Rello J, Cammararata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94
35. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in the treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6
36. Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004;188:760-6
37. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus aureus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21:263-74
38. Willke RJ, Glick HA, Li JZ, Rittenhouse BE. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. Int J Technol Assess Health Care 2002;18:540-54
39. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect 2003;4:57-70
40. López H, Li JZ, Balan DA, et al. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious Gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial. Clin Ther 2003;25:1846-71
41. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from IV vancomycin to PO linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003;25:3173-89
42. Nathwani D, Li JZ, Balan DA, et al, An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents 2004;23:315-24
43. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus(MRSA). Int J Antimicrob Agents 2005;26:442-8
44. Sharpe JN, Shively EH, Polk HC. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425-8
45. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006;40:1017-23
46. McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther 2007;29:469-77
47. McKinnon PS, Carter CT, Girase PG, et al. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag Care Interface 2007;20:23-34
48. Vinken A, Li Z, Balan D, et al. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J Hosp Infect 2001;49(Suppl A):S13-24
49. Glick HA, Willke RI, Rittenhouse BE, et al. Comparing hospital costs between linezolid and vancomycin in the treatment of methicillin-resistant staphylococcal species (MRSS) infections: a randomized multicenter clinical trial. Value Health 2002;5:565-6
50. Nathwani D, Barlow GD, Ajdukiewicz K, et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother 2003;51:391-6
51. Vinken AG, Li JZ, Balan DA, et al. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am J Ther 2003;10:264-74
52. Clincea R, Panza J, Abernathy K, McManus J. Pharmacoeconomic comparison of vancomycin and linezolid within the home health care setting of a Veterans Administration population [abstract 451]. 42nd Annual Meeting of the Infectious Diseases Society of America; 2004 September 30 - October 3; Boston
53. Sorensen SV, Hollenbeak CS, Baker TM, et al. Linezolid for the treatment of skin and soft-tissue MRSA infections - a cost-effective alternative to vancomycin: evidence from a multinational clinical trial. Value Health 2004;7:758-9
54. Schürmann D, de Cock E, Sorensen S, et al. Cost-effectiveness of linezolid versus vancomycin in complicated skin and soft-tissue infection due to suspected methicillin-resistant Staphylococcus aureus infection in Germany [abstract no. 1134_02_72]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 April 2 - 5; Copenhagen. Available from: http://www.blackwellpublishing.com/eccmid15/ abstract.asp?id=36728 [Last accessed November 2007]
55. Contreras-Hernández I, Mould J, Suárez-Nuñez F, Garduña-Espinosa J. Economic evaluation for the antimicrobial empiric treatment of hospitalized patients with ventilator-associated pneumonia due to Staphylococcus aureus in Mexico. Value Health 2006;9: A156
56. You Jh, Lee Gc, So Rk, et al. Linezolid versus vancomycin for prosthetic joint infections: a cost analysis. Infection 2007;35:265-70
57. Li JZ, Willke RJ, Balan DA, et al. Cost effectiveness analysis of linezolid vs teicoplanin for the treatment of serious Gram-positive bacterial infections in a multinational randomized trial. Value Health 2003;6:259-60
58. Gr_dsunewald T, de Cock E, Sorensen SV, et al. Cost-effectiveness of linezolid versus vancomycin in suspected methicillin-resistant Staphylococcus aureus in nosocomial pneumonia in Germany. Value Health 2004;7:758
59. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004;32:137-43
60. Grau S, Alvarez-Lerma F, Del Castillo A, et al. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother 2005;17:203-11
61. Grau S, Mateu-de Antonio J, Soto J, et al. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms. Pharm World Sci 2005;27:459-64
62. Machado AR, Arns Cda C, Follador W, Guerra A. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz J Infect Dis 2005;9:191-200
63. Aiello EC, Barcelona LI, de Vedia L, Stamboulian D. Cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia in Argentina. Value Health 2006;9:A155-6
64. Eandi M, Dale P, Sorensen S, et al. The economic impact of linezolid in the treatment of skin and soft tissue MRSA infections in Italy [abstract no. p1495]. 16th European Congress of Clinical Microbiology and Infectious Diseases; 2006 April 1 - 4; Nice. Available from: http://www.blackwellpublishing.com/eccmid16/abstract.asp?id=50290 [Last accessed November 2007]
65. Mullins CD, Kuznik A, Shaya FT, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 2006;28:1184-98
66. De Cock E, Timsit JF, Carlet J, et al. Cost-effectiveness of linezolid vs vancomycin in nosocomial pneumonia due to suspected methicillin-resistant Staphylococcus aureus in France. Value Health 2007;10:A439
67. De Cock E, Besnier JM, Dupon M, et al. Cost-effectiveness of linezolid vs vancomycin in skin and soft-tissue infection due to suspected methicillin-resistant Staphylococcus aureus in France. Value Health 2007;10:A439
68. Grau S, Aguado JM, Mateu-de Antonio J, et al. Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain. J Chemother 2007;19:398-409
69. Grau S, Aguado JM, Lalueza A, et al. Linezolid: una alternativa eficiente para el tratamiento de la infeccíon de la herida quirúrgica por SARM. Farm Hosp 2007;31:69
70. León C, Gómez Mateos JM, Catalá R, et al. Cost-effectiveness of linezolid versus vancomycin in the treatment of nosocomial pneumonia suspected to be caused by methicillin-resistant Staphylococcus aureus in Spain. Value Health 2007;10:A339-40
71. Patanwala A, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin 2007;23:185-93
72. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007;8:2381-400
73. Birmingham MC, Hassett JM, Schentag JJ, Paladino JA. Assessing antibacterial pharmacoeconomics in the intensive care unit. Pharmacoeconomics 1997;12:637-47
74. Nathwani D. Economic impact and formulary positioning: a new anti-Gram-positive antimicrobial. J Hosp Infect 2001;49(Suppl A):S33-41
75. Duttagupta S, Sorensen SV, Liu L. Cost-effectiveness of linezolid in Gram-positive infections: consistency of economic advantage from multiple health care systems. Value Health 2007;10:A163